Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pirenzepine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 2/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.98 |
| ▸ | USP2 | O75604 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.98 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.98 |
| ▸ | GMNN | O75496 | 1/20 | 0.96 |
| ▸ | APEX1 | P27695 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirenzepine SCHEMBL348603 | 1.00 | LMNA (0.98) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL41705 | 0.99 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL29793172 | 0.99 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL30553045 | 0.99 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL9254860 | 0.99 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL30548470 | 0.98 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL15300969 | 0.98 | LMNA (0.98) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL1462692 | 0.98 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL41704 | 0.98 | LMNA (1.00) | LMNACHRM2CHRM1USP2ALDH1A1 | |
| Pirenzepine SCHEMBL5987941 | 0.97 | LMNA (0.98) | LMNACHRM2CHRM1USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180922-A1 | TREATMENTS FOR DIABETIC NEUROPATHY | UNIV MANITOBA (CA) | 2024-06-06 | — | — | US | disclosed |
| US-11925649-B2 | Treatments for diabetic neuropathy | UNIVERSITY OF MANITOBA (CA) | 2024-03-12 | — | — | US | disclosed |
| US-10307428-B2 | Therapeutic compositions for diabetic symmetrical polyneuropathy | UNIVERSITY HEALTH NETWORK (CA) | 2019-06-04 | — | — | US | disclosed |
| US-20190046540-A1 | TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY HEALTH NETWORK (CA) | 2019-02-14 | — | — | US | disclosed |
| EP-3363439-A2 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | University Of Manitoba (CA) | 2018-08-22 | — | — | EP | disclosed |
| CN-103298473-B | Therapeutic compositions for diabetic symmetrical polyneuropathy | UNIVERSITY OF MANITOBA (CA) | 2015-07-29 | — | — | CN | disclosed |
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY OF MANITOBA (CA) | 2013-10-10 | — | — | US | disclosed |
| CN-103298473-A | Therapeutic compositions for diabetic symmetrical polyneuropathy | UNIV MANITOBA | 2013-09-11 | — | — | CN | disclosed |
| EP-2632468-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | University Of Manitoba (CA) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055018-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | UNIVERSITY OF MANITOBA (CA) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267506-A1 | THERAPEUTIC COMPOSITIONS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | CHRNA5, CHRM2, GAP43 | CHRM1 18/4885LMNA 2276/4885CHRM2 2/4885 |
| US-11925649-B2 | Treatments for diabetic neuropathy | CHRNA5, CHRNE, CHRM2 | CHRM1 19/4885LMNA 2061/4885CHRM2 3/4885 |
| US-20190046540-A1 | TREATMENTS FOR DIABETIC SYMMETRICAL POLYNEUROPATHY | CHRNA5, CHRM2, CHRNE | CHRM1 15/4885LMNA 1995/4885CHRM2 2/4885 |
| US-20240180922-A1 | TREATMENTS FOR DIABETIC NEUROPATHY | CHRNA5, CHRNE, CHRM2 | CHRM1 19/4885LMNA 2061/4885CHRM2 3/4885 |
| US-10307428-B2 | Therapeutic compositions for diabetic symmetrical polyneuropathy | CHRNA5, CHRM2, GAP43 | CHRM1 18/4885LMNA 2276/4885CHRM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.